0:00 Intro


0:25 Mazen’s lifelong commitment to furthering the field of precision medicine in liver disease research, fueled by a personal connection of his grandmother developing MASH cirrhosis


2:30 Breakthroughs in the field of metabolic dysfunction-associated steatotic liver disease (MASLD) since the beginning of Mazen’s career


5:30 The potential impact of Resmetirom, a new drug that could treat MASLD and MASH cirrhosis


8:45 Significant takeaways from 40+ investigational clinical studies of novel treatments for MASLD/MASH 


12:00 Alternatives to biopsies and potential tools for early, non-invasive diagnosis


19:00 Genetic determinants and risk factors for fatty liver disease


20:30 How Mazen uses genetic testing in the clinic for his patients


25:50 The impact of “miracle” weight loss drugs such as GLP-1s on patients with liver disease


29:30 The importance of early intervention to prevent late-stage cirrhosis 


33:00 How to tailor treatment to consider environmental and epigenetic factors that impact genetic penetrance for liver disease


36:00 Potential links between metabolism and neurodegenerative conditions


39:00 Upcoming developments in MASLD and MASH research

41:00 Mazen’s  relationship with his father, both as a dad and as a teacher